Literature DB >> 8267823

[HIV-associated Kaposi sarcoma in the head and neck area: a clinical, morphologic and therapeutic review].

A Riederer1, C Zietz, M Held.   

Abstract

Since 1987 233 HIV-infected patients have been treated at the Department of Otorhinolaryngology, Head and Neck Surgery of the Ludwig-Maximilians-University of Munich. 70% of these patients had advanced immunodeficiency disease (ARC and AIDS). 46 presented a Kaposi's sarcoma (KS) in the head and neck region. 91% were homosexual men. KS was most often located in the mouth (67%), oropharynx (65%) and skin (39.1%), while the larynx (10.9%), hypopharynx (8.7%), lymph nodes (6.5%) and nasopharynx (4.3%) were rarely involved. In 15 patients, a KS of the head and neck region was the initial symptom for the HIV-infection. Although the clinical features of this disease are typical, histological examination is required because differential diagnosis can show other rare diseases, such as bacillary angiomatosis, which are easily cured. The morphology of early plain or elevated KS exhibits more irregular vascular components while the nodular KS is dominated by sarcomatous cell lines. Immunohistochemical studies with antibodies to viral components revealed no reactivity to HIV-, HPV-, HSV-, EBV- and CMV-antigens. The best local treatment proved to be CO2- or ND:YAG-laser therapy. Cutaneous lesions were treated with camouflage or by fractionated radiotherapy. Advanced disease showed best response to systemic chemotherapy. Despite the advanced stage of immunodeficiency syndrome, an adequate local or systemic therapy can obviously improve the quality of life in HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8267823     DOI: 10.1055/s-2007-997940

Source DB:  PubMed          Journal:  Laryngorhinootologie        ISSN: 0935-8943            Impact factor:   1.057


  1 in total

1.  The histology of nasopharyngeal masses: a comparison between HIV positive and HIV negative patients.

Authors:  T Erasmus; T Daniller; J Goedhals; G Joubert; R Y Seedat
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-09-28       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.